Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCR300 in Relapsed/Refractory MDS
NCT05371730Phase 1Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of NCR-300 in myelodysplastic syndrome (MDS), sponsored by Nuwacell Biotechnologies. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 365 days. Planned start May 2022; status: not yet recruiting.
02
Drugs
NCR-300
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05371730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371730.